533 related articles for article (PubMed ID: 24836529)
1. Targeted anticancer therapy: overexpressed receptors and nanotechnology.
Akhtar MJ; Ahamed M; Alhadlaq HA; Alrokayan SA; Kumar S
Clin Chim Acta; 2014 Sep; 436():78-92. PubMed ID: 24836529
[TBL] [Abstract][Full Text] [Related]
2. Bridging cancer biology and the patients' needs with nanotechnology-based approaches.
Fonseca NA; Gregório AC; Valério-Fernandes A; Simões S; Moreira JN
Cancer Treat Rev; 2014 Jun; 40(5):626-35. PubMed ID: 24613464
[TBL] [Abstract][Full Text] [Related]
3. Ligand-based targeted therapy for cancer tissue.
Das M; Mohanty C; Sahoo SK
Expert Opin Drug Deliv; 2009 Mar; 6(3):285-304. PubMed ID: 19327045
[TBL] [Abstract][Full Text] [Related]
4. To exploit the tumor microenvironment: Passive and active tumor targeting of nanocarriers for anti-cancer drug delivery.
Danhier F; Feron O; Préat V
J Control Release; 2010 Dec; 148(2):135-46. PubMed ID: 20797419
[TBL] [Abstract][Full Text] [Related]
5. Nanotechnology-based combinational drug delivery: an emerging approach for cancer therapy.
Parhi P; Mohanty C; Sahoo SK
Drug Discov Today; 2012 Sep; 17(17-18):1044-52. PubMed ID: 22652342
[TBL] [Abstract][Full Text] [Related]
6. Nanoparticles-mediated drug delivery approaches for cancer targeting: a review.
Sultana S; Khan MR; Kumar M; Kumar S; Ali M
J Drug Target; 2013 Feb; 21(2):107-25. PubMed ID: 22873288
[TBL] [Abstract][Full Text] [Related]
7. The development of site-specific drug delivery nanocarriers based on receptor mediation.
Wang X; Li S; Shi Y; Chuan X; Li J; Zhong T; Zhang H; Dai W; He B; Zhang Q
J Control Release; 2014 Nov; 193():139-53. PubMed ID: 24862317
[TBL] [Abstract][Full Text] [Related]
8. Recent advances in ligand targeted therapy.
Trapani G; Denora N; Trapani A; Laquintana V
J Drug Target; 2012 Jan; 20(1):1-22. PubMed ID: 21942529
[TBL] [Abstract][Full Text] [Related]
9. pH-sensitive nano-systems for drug delivery in cancer therapy.
Liu J; Huang Y; Kumar A; Tan A; Jin S; Mozhi A; Liang XJ
Biotechnol Adv; 2014; 32(4):693-710. PubMed ID: 24309541
[TBL] [Abstract][Full Text] [Related]
10. Nanotechnology applied to overcome tumor drug resistance.
Gao Z; Zhang L; Sun Y
J Control Release; 2012 Aug; 162(1):45-55. PubMed ID: 22698943
[TBL] [Abstract][Full Text] [Related]
11. Targeting of nanoparticles in cancer: drug delivery and diagnostics.
Talekar M; Kendall J; Denny W; Garg S
Anticancer Drugs; 2011 Nov; 22(10):949-62. PubMed ID: 21970851
[TBL] [Abstract][Full Text] [Related]
12. Engineered nanoparticles for drug delivery in cancer therapy.
Sun T; Zhang YS; Pang B; Hyun DC; Yang M; Xia Y
Angew Chem Int Ed Engl; 2014 Nov; 53(46):12320-64. PubMed ID: 25294565
[TBL] [Abstract][Full Text] [Related]
13. Nanomedicine for targeted cancer therapy: towards the overcoming of drug resistance.
Shapira A; Livney YD; Broxterman HJ; Assaraf YG
Drug Resist Updat; 2011 Jun; 14(3):150-63. PubMed ID: 21330184
[TBL] [Abstract][Full Text] [Related]
14. Receptor mediated tumor targeting: an emerging approach for cancer therapy.
Mohanty C; Das M; Kanwar JR; Sahoo SK
Curr Drug Deliv; 2011 Jan; 8(1):45-58. PubMed ID: 21034422
[TBL] [Abstract][Full Text] [Related]
15. Tumor extracellular acidity-activated nanoparticles as drug delivery systems for enhanced cancer therapy.
Du JZ; Mao CQ; Yuan YY; Yang XZ; Wang J
Biotechnol Adv; 2014; 32(4):789-803. PubMed ID: 23933109
[TBL] [Abstract][Full Text] [Related]
16. Advances in novel drug delivery strategies for breast cancer therapy.
Dhankhar R; Vyas SP; Jain AK; Arora S; Rath G; Goyal AK
Artif Cells Blood Substit Immobil Biotechnol; 2010 Oct; 38(5):230-49. PubMed ID: 20677900
[TBL] [Abstract][Full Text] [Related]
17. Nanotechnology in cancer therapeutics: bioconjugated nanoparticles for drug delivery.
Sinha R; Kim GJ; Nie S; Shin DM
Mol Cancer Ther; 2006 Aug; 5(8):1909-17. PubMed ID: 16928810
[TBL] [Abstract][Full Text] [Related]
18. Acid active receptor-specific peptide ligand for in vivo tumor-targeted delivery.
Han L; Guo Y; Ma H; He X; Kuang Y; Zhang N; Lim E; Zhou W; Jiang C
Small; 2013 Nov; 9(21):3647-58. PubMed ID: 23649993
[TBL] [Abstract][Full Text] [Related]
19. Synergistic inhibition of breast cancer by co-delivery of VEGF siRNA and paclitaxel via vapreotide-modified core-shell nanoparticles.
Feng Q; Yu MZ; Wang JC; Hou WJ; Gao LY; Ma XF; Pei XW; Niu YJ; Liu XY; Qiu C; Pang WH; Du LL; Zhang Q
Biomaterials; 2014 Jun; 35(18):5028-38. PubMed ID: 24680191
[TBL] [Abstract][Full Text] [Related]
20. Drug development for cancer chemoprevention: focus on molecular targets.
Johnson KA; Brown PH
Semin Oncol; 2010 Aug; 37(4):345-58. PubMed ID: 20816505
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
